Medical/Pharmaceuticals

CES 2023: OMRON Healthcare Introducing Initiatives to Advance Its Vision of "Going for Zero" -- Elimination of Heart Attack and Stroke

KYOTO, Japan, Dec. 16, 2022 /PRNewswire/ -- OMRON Healthcare Co., Ltd. (hereinafter the Company) will exhibit at CES 2023 (*), the world's largest consumer tech show taking place inLas Vegas from Thursday, January 5, through Sunday, January 8. At the show, the Company will showcase the innovative...

2022-12-16 16:00 4314

Novavax Announces Pricing of $65 Million Public Offering of Common Stock

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of ...

2022-12-16 14:49 7109

Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of$150 million aggregate principal amount of its ...

2022-12-16 14:18 6554

Digital Mental Health Company, ThoughtFull, Partners with FWD to Provide Science-Backed and Technology-Enabled Mental Health Solutions for Customers in Hong Kong and Thailand

SINGAPORE, Dec. 16, 2022 /PRNewswire/ -- Asia's leading digital mental health company, ThoughtFull, continues to bring greater accessibility of its mental wellness solutions to corporate and consumer clients across theAsia region. Today, the firm announces that it is partnering with the FWD Group...

2022-12-16 11:00 4890

Bioved Pharmaceuticals, Inc. announces the results of its Phase III Randomized Clinical Trial in Moderate Covid-19 with Artovid-20®, a natural plant-based oral product

SAN JOSE, Calif., Dec. 16, 2022 /PRNewswire/ -- Published Nov 25, 2022 in the highly respected peer-reviewed journal Phytotherapy Research, results show statistically significant reduction in duration of illness and severity scores of the symptoms associated with Covid-19. In addition, statistica...

2022-12-16 01:30 3176

Nevisense for skin barrier evaluation included in large Australian birth cohort study

STOCKHOLM, Dec. 15, 2022 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that SciBase has received an order for skin barrier assessment products to be included  in one of the world's large...

2022-12-15 15:50 1962

Infermedica Celebrates Record Year, Accelerating Momentum Into 2023

$30M Series B funding round, launch of Medical Guidance Platform, and inclusion in CB Insights' Digital Health 150 list mark just some of the achievements in the 10th year since the company's founding DENVER, Dec. 15, 2022 /PRNewswire/ -- Infermedica – a leading digital health company specializi...

2022-12-15 14:18 2447

International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children's Cancers

ACC, NCCN, ACS, and CHAI collaborate to launch new NCCN Harmonized Guidelines for Sub-Saharan Africa focused on pediatric cancers; available free at NCCN.org/harmonized. DAR ES SALAAM, Tanzania and PLYMOUTH MEETING, Pa., Dec. 15, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NC...

2022-12-15 14:07 2497

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Ph...

2022-12-15 14:00 4030

IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

GUANGZHOU, China , Dec. 15, 2022 /PRNewswire/ -- On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as "Biosyngen") made an announcement on the approval granted by the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) for the company's IND appl...

2022-12-15 13:08 5594

XINGIMAGING and MITRO BIOTECH CO., LTD. to DELIVER FULL-SERVICE CRO OPERATIONS TO CHINA

NEW HAVEN, Conn., Dec. 15, 2022 /PRNewswire/ -- XINGIMAGING, LLC, and MITRO Biotech Co., Ltd. each highly recognized for drug development and imaging solutions, announce today that they will join forces to provide comprehensive contract research services inChina. The company will be a leading par...

2022-12-15 12:53 3304

Stemirna receives Emergency Use Authorization from Laos for its proprietary mRNA vaccine

SHANGHAI, Dec. 14, 2022 /PRNewswire/ -- On December 8, 2022, Stemirna Therapeutics Co., Ltd. (Stemirna), a Chinese biotech startup specialized inmRNA technology-based drug development, received an Emergency Use Authorization (EUA) from the Food and Drug Department under the Ministry of Health of ...

2022-12-15 12:27 6461

CGTN: How China strengthens vaccine cooperation to battle COVID-19

BEIJING, Dec. 15, 2022 /PRNewswire/ -- Since the outbreak of COVID-19, the world has raced against time, battling the pandemic as it wreaked havoc across the globe. Developing safe and effective vaccines is one of the most crucial steps in the fight against the virus. For the last nearly three y...

2022-12-15 09:16 4153

"Gowajee" - a Thai Speech-Recognition AI from Chula

BANGKOK, Dec. 15, 2022 /PRNewswire/ -- Chula Engineering professors have designed "Gowajee", a Thai-language speech recognition AI with the accuracy of a native speaker that keeps users' data secure – now rolled out in call centers, and being used for depression patients screening.

2022-12-15 09:00 5360

Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease

ROCKVILLE, Md. and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Innovent Biologics ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other m...

2022-12-15 08:00 5472

Alternative Bio Launches with USD 15M Series Seed Financing Led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund

SINGAPORE, Dec. 15, 2022 /PRNewswire/ -- Alternative Bio Inc. ("ABio"), a privately held biotechnology company developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes announced today its $15 million Series Seed financing co-led by Eight Roads Ve...

2022-12-15 08:00 4312

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities Clinically validated mRNA platform is shown to generate differentiated products across a range of indications SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- Everest M...

2022-12-15 08:00 8060

Novavax Announces Proposed $125 Million Public Offering of Common Stock

GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its c...

2022-12-15 05:39 5685

Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ

Dose escalation cohort study is evaluating the safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with isSCC GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock...

2022-12-14 23:47 3713

Circulating Tumor Cell detection by Menarini Group's CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease

Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs)with Menarini Silicon Biosystems' CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at...

2022-12-14 21:00 2165
1 ... 273274275276277278279 ... 381